Heart Failure Trial Tests New Valve Procedure in Major Cardiology Study

The trial, known as TRIC-I-HF, focuses on the tricuspid valve — one of four valves in the heart, sitting on the right side and controlling blood flow between the heart’s upper and lower chambers. When this valve leaks badly, a condition called tricuspid regurgitation (TR), blood flows backwards rather than forwards, placing extra strain on the heart. The study was presented at ESC Congress and published simultaneously in the New England Journal of Medicine.

A paired editorial, also published in the journal, examines transcatheter tricuspid-valve intervention — a keyhole procedure done through a thin tube inserted into a blood vessel, avoiding open-heart surgery. This approach has attracted growing attention among cardiologists because many patients with severe TR are considered too frail or unwell for traditional surgery.

Severe tricuspid regurgitation is closely associated with heart failure, and treating it has historically been difficult. The question the trial sets out to answer is whether intervening on the valve — rather than managing heart failure with medication alone — produces measurable benefits for patients.

The full results and the editorial are available through the New England Journal of Medicine.

—

*Anyone concerned about heart symptoms should contact their GP or call NHS 111. In an emergency, call 999.*